LAMIVUDINE

SynDRA canonical compound SYN0001539 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Mechanism of action	nucleoside reverse transcriptase inhibitor
Indication	acquired immunodeficiency syndrome (AIDS) \| hepatitis B \| human immunodeficiency virus (HIV-1) \| human immunodeficiency virus (hiv-1), acquired immunodeficiency syndrome (aids), hepatitis b
Disease area	infectious disease

All known targets

DCK
HBcAg
HIV RT
P
pol

Mechanisms of action (all sources)

nucleoside reverse transcriptase inhibitor
Modulator
P INHIBITOR
pol INHIBITOR

Drug classes

Nucleoside Reverse Transcriptase Inhibitors
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors
Reverse Transcriptase Inhibitors

ATC classes

J05A · DIRECT ACTING ANTIVIRALS

Cross-references

PubChem CID: 60825
ChEMBL: CHEMBL141
DrugBank: DB00709
ChEBI: CHEBI:63577
KEGG: D00353
RxNorm: 68244
PDB: 3TC
Wikipedia: Lamivudine
TTD: D07TQV
LINCS BRD: BRD-K02992638

Synonyms

Reported adverse events

Lactic acidosis
Hepatitis
Hepatomegaly
Hypersensitivity
Hepatitis B
Lactic acid
Myopathy
Acidosis
P
Se
DIC
Infection

Look up LAMIVUDINE in the interactive SynDRA portal →